A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS)
Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
GEn1E-1124-002 is a two-part Phase 2 study to evaluate the safety and tolerability of
GEn-1124 in subjects with ARDS. Treatment with IV infusion dosing within 48 hours of ARDS
diagnosis. Subjects will be given a second dose approximately 8 hours after the first dose
and will continue with twice daily dosing (BID regimen) for 5 days.